Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐<scp>BCMA CAR</scp> T‐cell‐based therapyYuekun Qi, Jiang Cao, Hujun Li et al.|American Journal of Hematology|2024Cited by 21
Identification and pharmacological properties of 2-(1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-INACA), N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (ADB-INACA), and N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)Fangqi Cao, Ping Shi, Shuchen Yu et al.|Journal of Pharmaceutical and Biomedical Analysis|2024Cited by 7
pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcers: A Phase II, Double-Blind, Randomized Placebo-Controlled TrialYongquan Gu, Wu Zuze, Mingzhang Li et al.|Research Square|2020Cited by 0
Identification and Pharmacological Properties of 2-(1h-Indazole-3-Carboxamido)- 3,3-Dimethylbutanoate (Mdmb-Inaca), N-(1-Amino-3,3-Dimethyl-1-Oxobutan-2-Yl)- 1h-Indazole-3-Carboxamide (Adb-Inaca), and N-(1-Amino-3,3-Dimethyl-1-Oxobutan- 2-Yl)-1-Hexyl-1h-Indazole-3-Carboxamide (Adb-Hinaca)Fangqi Cao, Ping Shi, Shuchen Yu et al.|SSRN Electronic Journal|2024Cited by 0